Mind Medicine (MindMed) (MNMD) Competitors $9.76 +0.04 (+0.41%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$9.68 -0.08 (-0.82%) As of 07/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock MNMD vs. APLS, XENE, NAMS, GMTX, BHC, AGIO, TWST, INDV, RXRX, and DNLIShould you be buying Mind Medicine (MindMed) stock or one of its competitors? The main competitors of Mind Medicine (MindMed) include Apellis Pharmaceuticals (APLS), Xenon Pharmaceuticals (XENE), NewAmsterdam Pharma (NAMS), Gemini Therapeutics (GMTX), Bausch Health Cos (BHC), Agios Pharmaceuticals (AGIO), Twist Bioscience (TWST), Indivior (INDV), Recursion Pharmaceuticals (RXRX), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry. Mind Medicine (MindMed) vs. Its Competitors Apellis Pharmaceuticals Xenon Pharmaceuticals NewAmsterdam Pharma Gemini Therapeutics Bausch Health Cos Agios Pharmaceuticals Twist Bioscience Indivior Recursion Pharmaceuticals Denali Therapeutics Apellis Pharmaceuticals (NASDAQ:APLS) and Mind Medicine (MindMed) (NASDAQ:MNMD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership. Which has more risk & volatility, APLS or MNMD? Apellis Pharmaceuticals has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, Mind Medicine (MindMed) has a beta of 2.45, indicating that its stock price is 145% more volatile than the S&P 500. Do analysts recommend APLS or MNMD? Apellis Pharmaceuticals presently has a consensus price target of $40.00, indicating a potential upside of 104.19%. Mind Medicine (MindMed) has a consensus price target of $24.00, indicating a potential upside of 145.90%. Given Mind Medicine (MindMed)'s stronger consensus rating and higher possible upside, analysts clearly believe Mind Medicine (MindMed) is more favorable than Apellis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apellis Pharmaceuticals 0 Sell rating(s) 9 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.62Mind Medicine (MindMed) 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Is APLS or MNMD more profitable? Mind Medicine (MindMed) has a net margin of 0.00% compared to Apellis Pharmaceuticals' net margin of -28.83%. Mind Medicine (MindMed)'s return on equity of -40.33% beat Apellis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Apellis Pharmaceuticals-28.83% -99.19% -25.35% Mind Medicine (MindMed) N/A -40.33%-32.13% Does the media prefer APLS or MNMD? In the previous week, Mind Medicine (MindMed) had 1 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 5 mentions for Mind Medicine (MindMed) and 4 mentions for Apellis Pharmaceuticals. Apellis Pharmaceuticals' average media sentiment score of 1.14 beat Mind Medicine (MindMed)'s score of 0.71 indicating that Apellis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apellis Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mind Medicine (MindMed) 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in APLS or MNMD? 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. Comparatively, 27.9% of Mind Medicine (MindMed) shares are held by institutional investors. 6.5% of Apellis Pharmaceuticals shares are held by insiders. Comparatively, 2.5% of Mind Medicine (MindMed) shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger earnings & valuation, APLS or MNMD? Mind Medicine (MindMed) has lower revenue, but higher earnings than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Mind Medicine (MindMed), indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApellis Pharmaceuticals$781.37M3.15-$197.88M-$1.79-10.94Mind Medicine (MindMed)N/AN/A-$108.68M-$1.29-7.57 SummaryMind Medicine (MindMed) beats Apellis Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Mind Medicine (MindMed) News Delivered to You Automatically Sign up to receive the latest news and ratings for MNMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MNMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNMD vs. The Competition Export to ExcelMetricMind Medicine (MindMed)MED IndustryMedical SectorNASDAQ ExchangeMarket Cap$737.40M$3.06B$5.74B$9.54BDividend YieldN/A2.36%4.71%4.02%P/E Ratio-7.5721.3228.4120.06Price / SalesN/A300.85443.6492.77Price / CashN/A42.6036.1858.54Price / Book3.048.328.655.87Net Income-$108.68M-$55.19M$3.25B$258.89M7 Day Performance9.91%5.86%4.31%3.75%1 Month Performance49.01%19.30%11.60%12.29%1 Year Performance3.89%4.32%35.38%17.86% Mind Medicine (MindMed) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNMDMind Medicine (MindMed)1.9816 of 5 stars$9.76+0.4%$24.00+145.9%+3.9%$737.40MN/A-7.5740News CoverageAPLSApellis Pharmaceuticals4.1968 of 5 stars$19.91+2.4%$39.79+99.8%-50.7%$2.50B$781.37M-11.12770Upcoming EarningsXENEXenon Pharmaceuticals3.7436 of 5 stars$32.60+1.2%$54.82+68.2%-31.1%$2.50B$9.43M-10.09210Positive NewsOptions VolumeNAMSNewAmsterdam Pharma3.5313 of 5 stars$22.17+2.9%$42.89+93.5%+25.1%$2.49B$47.14M-11.794GMTXGemini TherapeuticsN/A$56.91-1.9%N/A+38.0%$2.47BN/A-56.9130BHCBausch Health Cos2.9539 of 5 stars$6.34-1.3%$7.30+15.2%+12.9%$2.34B$9.63B-57.5920,700News CoverageUpcoming EarningsAGIOAgios Pharmaceuticals4.3547 of 5 stars$39.23+0.5%$58.60+49.4%-16.8%$2.27B$37.04M3.49390Upcoming EarningsAnalyst ForecastTWSTTwist Bioscience4.3628 of 5 stars$37.80-0.6%$50.40+33.3%-38.0%$2.26B$312.97M-11.63990News CoverageINDVIndivior1.1168 of 5 stars$15.62+1.0%$17.00+8.8%+34.0%$2.15B$1.17B-50.391,051News CoverageUpcoming EarningsAnalyst ForecastRXRXRecursion Pharmaceuticals0.783 of 5 stars$5.28flat$7.00+32.6%-22.3%$2.15B$59.82M-2.98400DNLIDenali Therapeutics4.1778 of 5 stars$14.69+1.2%$33.71+129.5%-43.3%$2.13B$330.53M-5.50430News CoveragePositive NewsUpcoming Earnings Related Companies and Tools Related Companies APLS Alternatives XENE Alternatives NAMS Alternatives GMTX Alternatives BHC Alternatives AGIO Alternatives TWST Alternatives INDV Alternatives RXRX Alternatives DNLI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNMD) was last updated on 7/27/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredThe big winner of Crypto week?It’s Crypto Week at the White House — and the sector is moving from fringe to full-scale adoption. With Bit...Weiss Ratings | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mind Medicine (MindMed) Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mind Medicine (MindMed) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MNMD Stock Alerts